Tag Archives: Drug Approvals

Look Back – Drug Approvals First Half of 2020 Amidst the COVID Challenge

Posted on July 28, 2020 by Mark Senak

As the year began, no one really thought that within a few months, the systems upon which we rely on for just about everything would be so severely disrupted and tested by the presence of something we cannot even see … Continue reading →

Posted in Approval Announcements, FDA Policy | Tagged , , | Comments Off on Look Back – Drug Approvals First Half of 2020 Amidst the COVID Challenge

AdComm Drop-off in 2019 – FDA Consults Fewer Experts in 2019

Posted on November 13, 2019 by Mark Senak

The system of FDA Advisory Committees is in place so that when FDA needs advice – either on policy development, reviewing an issue with an already approved medicine, or regarding new drug approvals – the agency has a lot of … Continue reading →

Posted in Uncategorized | Tagged , , , | Comments Off on AdComm Drop-off in 2019 – FDA Consults Fewer Experts in 2019

Sorting it Out – FDA AdComm Review for 2018

Posted on February 21, 2019 by Mark Senak

In 2017, the Advisory Committees voted to recommend approval 71.4 percent of the time; in 2018 it was 66.6 percent. Continue reading →

Posted in Advisory Committee Prepapartion | Tagged , , , | 1 Comment